Inhibikase Therapeutics Inc. reported its financial results for the first quarter ending March 31, 2025, showcasing a significant increase in net loss compared to the previous year. The company reported a net loss of $13.7 million for the quarter, which is a considerable increase from the $4.6 million net loss in the same period in 2024. Research and development expenses also rose sharply to $10.5 million from $2.8 million in the previous year, largely due to a $7.4 million non-cash charge related to the acquisition of CorHepta. The company's selling, general, and administrative expenses increased to $5.2 million from $2.0 million in 2024. As of March 31, 2025, Inhibikase had $93.2 million in cash, cash equivalents, and marketable securities. In business developments, the company has been advancing its lead candidate, IKT-001, into a late-stage clinical trial program for pulmonary arterial hypertension (PAH). The company is preparing to finalize the study design for a Phase 2b clinical study of IKT-001 in PAH and expects to initiate this study in the second half of 2025. The company recently appointed several key executives, including a new CEO, President and Head of Research & Development, Chief Scientific Officer, and Chief Financial Officer, to strengthen its leadership team.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.